What Kiromic BioPharma, Inc. Shareholders Need to Know About the Lead Plaintiff Process Under the PSLRA

Contact Kiromic BioPharmastock loss lawyer Timothy L. Miles today about a Kiromic BioPharma class action lawsuit

The Kiromic BioPharma class action lawsuit was was file by an investor who suffered losses Kiromic BioPharma stock and is captioned Karp v. Kiromic BioPharma, Inc., No. 22-cv-06690 (S.D.N.Y.) The Kiromic BioPharma class action lawsuit charges certain of its top executive officers and directors, as well as the successor to the Offering’s underwriter with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934.

The Kiromic BioPharma class action lawsuit seeks to represent purchasers or acquirers of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (a) common stock pursuant to the registration statement filed and a final prospectus (together, the “Offering Documents”) issued in connection with Kiromic BioPharma’s public offering that closed on July 2, 2021 (the “Offering”); and/or (b) common stock between June 25, 2021 and August 13, 2021, inclusive (the “Class Period”).

If you suffered losses in Kiromic BioPharma stock and wish to serve as lead plaintiff of the Kiromic BioPharma class action lawsuit, or have any other questions, please provide your information  by completing the contact form at the bottom of the page.  You can also contact Kiromic BioPharma Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected]. 
​
Lead plaintiff motions for the Kiromic BioPharma class action lawsuit must be filed with the court no later than October 4, 2022. Read on for more on the lead plaintiff process.

The Lead Plaintiff Process in the Kiromic BioPharma Class Action Lawsuit

The Private Securities Litigation Reform Act of 1995 (“PSLRA) permits any investor who purchased and suffered losses in Kiromic BioPharma to seek appointment as lead plaintiff in the Kiromic BioPharma class action lawsuit. Under the PSLRA, after a complaint is filed, a plaintiff has no later than 20 days to circulate notice to shareholders about the filing of the complaint notifying shareholders that “not later  than 60 days after the date on which the notice is published, any member of the purported class may move the court to serve as lead plaintiff of the purported class.” 15 U.S. Code § 78u–4(a)(3)(A)(i)-(iii.).  Thus, pursuant to the PSLRA, Lead plaintiff motions for the Kiromic BioPharma class action lawsuit must be filed with the court no later than October 4, 202 after publication of the notice.
​
A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  15 U.S. Code § 78u–4(a)(3)(B)(iii)(I)(bb)-(cc). A lead plaintiff is a fiduciary and acts on behalf of all other class members in directing the class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Kiromic BioPharma stock, and have further questions, contact Kiromic BioPharma Stock Loss Lawyer Timothy L. Miles today.

Lead plaintiff motions for the Kiromic BioPharma class action
lawsuit must be filed with the court no later than October 4, 2022

Contact a Kiromic BioPharma Stock Loss Lawyer if You Suffered Losses in Kiromic BioPharma Stock

​If you suffered losses in Kiromic BioPharma stock, contact Kiromic BioPharmastock loss lawyer Timothy L. Miles today about a Kiromic BioPharma class action lawsuit, and see what a Kiromic BioPharma stock Stock Loss Lawyer can do for you.

Timothy L. Miles, Esq.

Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles was recentely selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, and more.